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ABSTRACT
The emergence of virulent, antibiotic-resistant Clostridium difficile ribotypes over the past thirty
years has greatly concerned both the medical and research communities. As of 2010, C. difficile has
surpassed methicillin-resistant Staphylococcus aureus (MRSA) as a cause of nosocomial infections and is
now found in both healthcare settings and outside communities in the United States. Attendant-borne
transmission in hospitals has been associated with the evolution of increased virulence in other nosocomial
pathogens, but evolutionary theory has yet to be applied to the epidemiology and virulence of C. difficile.
Differences between nosocomial C. difficile infections (CDI) and community-associated CDI (CA-CDI)
mortality and ribotype distributions were evaluated in order to determine if attendant-borne transmission in
hospitals and long-term care facilities favors highly virulent C. difficile ribotypes. Analysis of the current
literature on C. difficile revealed that nosocomial CDIs were significantly more virulent and associated with
greater mortality than CA-CDIs. Additionally, the data indicate that ribotypes 027 and 001/smz are
particularly well-adapted for transmission in healthcare settings given their prominent role in nosocomial
CDI but near absence in healthy C. difficile carriers in the outside community. These findings suggest that
interventions that prevent attendant borne transmission may aid in the incidence reduction and virulence
modification of C. difficile infections.

INTRODUCTION
Nosocomial Infections and Attendant-Borne Transmission
Nosocomial infections are a major contributor to morbidity and mortality globally. The World
Health Organization estimates that 7 out of every 100 hospitalized patients in developed countries, and 10
out of every 100 in developing countries will contract at least one healthcare-associated infection (HAI)
during the course of their stay (WHO 2013). In the United States, nosocomial infections were diagnosed in
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over 1.7 million people and associated with nearly 100,000 deaths in 2002 (Klevens, Edwards et al. 2007).
Nosocomial infections are generally transmitted by attendants, such as doctors and nurses, who transfer the
causal pathogens to infected patients on hands and gloves directly or indirectly through contamination of
materials and equipment (i.e. fomites) in the hospital environment (Jameson et al. 1954, Knittle et al. 1975).
Evolutionary theory suggests that such attendant-borne transmission will favor evolution of
increased virulence. The movement of attendants from one patient to another allows patients immobilized
by severe illness to infect large numbers of other patients by way of attendants’ contaminated hands.
Consequently, highly exploitative pathogens can proliferate more extensively in environments that favor
attendant-borne transmission and hence achieve an evolutionary fitness advantage over milder variants
(Ewald 1988, Ewald 1991). In the outside community, infected hosts generally must move into contact with
new hosts. This sort of transmission favors mildly exploitative organisms that do not significantly
incapacitate their hosts. Accordingly, very sick, immobilized individuals cannot serve as a source of
extensive transmission in the outside community.
Persistence in the environment outside of a host is also thought to favor the evolution of increased
virulence by augmenting a pathogen’s ability to be transmitted very sick infected hosts (Walther and Ewald
2004). Such “sit and wait” organisms have relatively low associated fitness costs with exploiting the host
to the point of immobilization and even death because the organism can persist on a contaminated surface
or on the host’s body and still be transmitted via the movement of uninfected individuals in the
contaminated environment. Accordingly, persistence in the environment can enhance attendant-borne
transmission by increasing possibilities for transmission via fomites.
Several attendant-borne pathogens are known to cause severe disease in hospital settings (Ewald
1991, Cooper et al. 1999, Harbarth et al. 2003), including Staphylococcus aureus (Shinefield 1976), nontyphoid Salmonella (Mushin 1948, Rubbo 1948, Mackerras and Mackerras 1949), and Escherichia coli
(Jacobs et al. 1970, Boyer et al. 1975). Studies of E. coli in neonates at a Cincinnati hospital found that
infections were less severe when they were derived from mothers who had been infected outside the hospital
2

as opposed to during their hospital stay (Cooper et al. 1956). Similar trends are seen in cases of non-typhoid
Salmonella; infections acquired outside of hospitals or in situations where attendant-borne transmission
plays a minimal role are rarely lethal (Kohler 1964), but hospital outbreaks are often severe and deadly
(Ewald 1988). Attendant-borne transmission of non-typhoid Salmonella in Australian hospitals during 1946
and 1947 resulted in mortality rates of 15% and 38% respectively (Mushin 1948, Rubbo 1948, Mackerras
and Mackerras 1949) whereas the case mortality rate is usually <1% in developed countries (Chimalizeni
et al. 2010).
These associations accord with the hypothesis that attendant-borne transmission in healthcare
facilities favors increased virulence, but a direct comparison of virulence in attendant-borne strains relative
to community strains has not, to my knowledge, been presented. The increasingly detailed understanding
of nosocomial Clostridium difficile and the recent reports of hypervirulent strains makes it a highly-relevant
candidate for such comparisons.
Epidemiology of Clostridium difficile
Clostridium difficile is a gram-positive, bacillus bacterium well-known for causing nosocomial
infections of the intestinal tract in healthcare settings. One commonly accepted model of C. difficile
infection, pathogenesis, and transmission involves recent host exposure to antibiotics, which supposedly
leads to dysbiosis (i.e. microbial imbalance) and compromises the colonization barrier, resulting in infection
with either endogenous or exogenous C. difficile. Symptomatic and asymptomatic infections cause
shedding of C. difficile spores in the feces, which can persist on fomites and other surfaces and contaminate
the hands of attendants (Bartlett 2006, Riggs et al. 2007, Deneve et al. 2009). A myriad of other associated
risk factors for C. difficile infection (CDI) have been suggested in the literature, including hospitalization,
old age ( >65 years), use of proton-pump inhibitors (PPIs), and comorbidities such as inflammatory bowel
disease, although antibiotic exposure is considered to be the most important (Barbut et al. 1996, Jump et al.
2007, Deneve et al. 2009). The exact mechanism of dysbiosis and the true role of antibiotics in C. difficile
colonization remains unclear. Antibiotics with very similar inhibitory spectra do not initiate CDI at the
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same rates; moreover, antibiotics associated with low disruption of the intestinal microbiota can be
associated with CDI (Settle et al. 1998, Gerding 2004, Baines et al. 2005). Such findings suggest that
additional mechanisms aside from disruption of the colonization barrier via the elimination of competing
bacterial species may be playing an important role in C. difficile colonization (Settle et al. 1998, Baines et
al. 2005).
C. difficile first began capturing the attention of the medical and scientific community in the late
1970s due to its role in cases of antimicrobial-associated diarrhea, colitis, and pseudomembranous colitis.
Interest continued to grow once it was recognized as a cause of morbidity and mortality among hospitalized
elderly patients (Freeman et al. 2010). The reported incidence of C. difficile-associated diarrhea (CDAD)
rapidly grew in the United States from fewer than 150,000 cases in 2000 to an estimated 500,000 cases in
2006 (Redelings et al. 2007, Pamer 2013). Redelings et al. (2007) reported a 35%-per-year increase in
CDAD-related deaths between 1999 and 2004; over half of this increase was associated with an increase in
the incidence of hospitalizations with severe infections (Redelings et al. 2007, Zilberberg et al. 2008).
CDAD discharges from U.S. hospitals also doubled between 2000 and 2005 (Zilberberg et al. 2008). A 13year retrospective Canadian study of C. difficile infections (CDIs) reported an increase in incidence of 35.6
cases per 100,000 in 1991 to 156.3 cases per 100,000 in 2003; the 30-day mortality rate of patients nearly
tripled in this period from 4.7% to 13.8% (Pepin et al. 2004). In the Netherlands, deaths associated with
CDAD or pseudomembranous colitis more than doubled from an age-standardized mortality rate of 11 per
million population in 1999 to 24 per million in 2004 (Goorhuis et al. 2007, Freeman et al. 2010).
The growing problem of CDIs in the U.S., Canada, and England has been attributed in part to the
emergence of highly virulent strains (McDonald et al. 2004, Pepin et al. 2004, Wilcox et al. 2012). C.
difficile is a genetically diverse bacterial species with a common ancestor dating back to 1.1 to 85 million
years ago, yet phylogenetic analysis has revealed that disease-causing C. difficile ribotypes are relatively
new, with the epidemic 027 ribotype emerging only thirty years ago (He et al. 2010). Prior to 2000, highly
virulent variants such as ribotype 027/NAP1/BI accounted for <1% of isolates collected in the United States
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(McDonald et al. 2005). During the first decade of the 21st century, the 027 ribotype spread across most of
the North America and Europe, with 16 European countries (Austria, Belgium, Denmark, Germany,
Hungary, Finland, France, Ireland, Luxembourg, the Netherlands, Norway, Poland, Spain, Sweden,
Switzerland, and the United Kingdom) reporting outbreaks by 2008 (Freeman et al. 2010). CDI mortality
in Quebec was more than four times greater than for the rest of Canada combined; this increased mortality
was thought to be due at least in part to ribotype 027, which was most frequently isolated in Quebec,
Ontario, and British Columbia (Gravel et al. 2009). A study conducted in the U.S., representing 45
locations, 25 states, and 548 isolates collected between 2005 and 2007, found that ribotype 027 (which
corresponds to restriction endonuclease analysis group BI) composed 54% of the collection, was found in
80% of the states, and 82% of the individual hospitals (Cheknis et al. 2009). An earlier nation-wide study
conducted during CDI outbreaks between 2000 and 2003 similarly found that 51% of isolates were ribotype
027 (McDonald et al. 2005). Japan also recorded a shift in their C. difficile ribotype population between
2000 and 2004 when the predominant ribotype isolated from CDI patients changed from a milder ribotype,
known as ribotype a, to the more virulent epidemic strain, known as ribotype smz (Sawabe et al. 2007).
This ribotype is thought to be synonymous with ribotype 001 (Freeman et al. 2010), which seems to have
been slowly replacing ribotype 027 as of 2008 across 34 European countries (Bauer et al. 2009). Out of the
64 ribotypes identified in 7 hospitals sampled per country, ribotype 001 comprised 10% of isolates whereas
027 comprised 5% (Bauer et al. 2009). Curiously enough, two lesser-known ribotypes, 014 and 020,
accounted for 15% of the isolates (Bauer et al. 2009). Cheknis et al. (2009) found that ribotype 027’s
predominance has recently diminished in Europe, with only 3 out of 13 countries surveyed reporting it as
the most common strain. They noted that ribotype 001 (their REA group J) was the most frequently isolated
in Europe. Despite the recently observed changes in the epidemiology of C. difficile in Europe, ribotype
027 continues to persist as the predominant ribotype associated with CDI outbreaks in both Canada and the
United States (Janezic et al. 2012).
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Interpretations of the overall trends in C. difficile virulence is complicated by the increasing
antibiotic-resistance of some C. difficile strains, even to third generation cephalosporins and
fluoroquinolones (Razavi et al. 2007). Moreover, treatment with fluoroquinolones has not only been
demonstrated to be ineffective but also to enhance sporulation, vegetative cell growth, and toxin production
in certain ribotypes, most notably 027 and 001 (Saxton et al. 2009). Clindamycin, which had previously
been thought to be “protective” against CDI development, was rendered useless against certain 027 variants
that were first reported in Switzerland in 2008 (Freeman et al. 2010). These changes in the epidemiology
and pathology of C. difficile infections have been alarming for both the medical and research communities.
As Voelker (2010) states, “During the past decade, mutations in the bacterium have transformed C. difficile
from a rare nosocomial infection to one that can spread rapidly in hospitals and has spilled out into the
community. Now infections of healthy individuals with few or no risk factors is not uncommon, and
increasing recurrence rates have been reported.” With a relapse and recurrence rate of 20%, CDAD imposes
a financial burden of nearly $1 billion dollars in healthcare costs per year (Dubberke et al. 2008, Cohen et
al. 2010). These health-related and economic consequences warrant greater attention with respect to the
emergence and control of highly virulent pathogens.
This study evaluates a central prediction of the hypothesis that attendant-borne transmission favors
increased virulence, namely that ribotypes of high virulence should be associated with transmission in
healthcare settings. It assesses the extent to which Clostridium difficile ribotypes are transmitted in
healthcare settings as opposed to in the outside community and whether any nosocomial ribotypes are more
virulent than community ribotypes. Finally, it considers implications for the control of C. difficile-related
illness.
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ATTENDANT-BORNE TRANSMISSION, DURABILITY, AND VIRULENCE OF C. DIFFICILE
Circulation in Hospitals Relative to the Outside Community
The transmission cycles of Clostridium difficile are only partially understood and are widely
debated, leading to uncertainty and disagreement over the roles of healthcare institutions, healthcare
personnel, and asymptomatic carriers in the spread of CDIs (Clabots et al. 1992, Samore et al. 1996, Settle
et al. 1998, Riggs et al. 2007). Depending upon study parameters, some researchers narrowly classify
nosocomial CDIs as those with a direct link to hospitals or long-term care facilities (LTCFs). Others define
nosocomial CDIs more broadly to include healthcare contacts that occur during visits to a hospitals, LTCFs,
and doctor’s offices. To account for the variation in definitions, this paper will use the terms “broadly
nosocomial” and “narrowly nosocomial” to clarify the origins of CDI when possible.
Hospitalization and residence in a LTCF are both known to be associated with an increased risk for
narrowly nosocomial C. difficile infections, but the source of infection is often ambiguous unless extensive
and rigorous strain typing and epidemiological tracking are implemented during outbreaks (Freeman et al.
2010). The increase in apparent community-associated CDAD over the past two decades has led some to
suggest that transmission from individuals in the community may play an important role in introducing
virulent C. difficile strains to hospitals and patients and that nosocomial transmission has been greatly
overestimated (Khanna and Pardi 2010). However, a recent Centers for Disease Control and Prevention
study concluded that 94% of symptomatic C. difficile infections could be traced back to hospitals or other
healthcare settings despite the majority of infections (74%) having symptom onset in the outside community
(McDonald et al. 2012). An earlier prospective cross-over study of elderly patients in the United Kingdom
also reported similar findings and concluded from DNA fingerprinting analysis that “most infections arose
from strains acquired from the hospital environment” (Settle et al. 1998). Length of hospital stay has also
been directly correlated with acquisition of C. difficile (Clabots et al. 1992, Riggs et al. 2007). These
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findings lend credence to the notion that hospitals and other healthcare facilities may inadvertently play a
major role in transmission of C. difficile. The critical question, however, is whether the nosocomial strains
are distinct from and inherently more virulent than the strains that cycle predominantly in the outside
community.
A PCR ribotyping study on strains isolated during 1999-2000 from three hospitals in Örebro
County, Sweden revealed one ribotype (SE17) that was especially well-suited for transmission in hospitals;
it accounted for 26% of nosocomial-associated CDAD cases versus only 6% of community-associated cases
(Norén et al. 2004). Similar findings were reported for ribotype 001 in the United Kingdom prior to the
peak years of the ribotype 027 outbreaks. Nearly 55% of isolates from hospitals in the United Kingdom
were identified as ribotype 001 whereas only 7.5% of community CDIs were attributable to 001 (Stubbs et
al. 1999). It has been suggested that this particular ribotype has an increased attack rate or greater ability
for nosocomial spread (Akerlund et al. 2006). The presence of this hospital-associated ribotype in the
outside community indicates that the hospital-associated ribotypes can be found in the outside community
but does not reveal the extent to which these ribotypes are cycling outside of hospital settings. If hospital
settings favor highly virulent ribotypes, these may cycle back to the hospital relatively quickly because of
their propensity for causing severe illness, which may lead to the hospitalization of infected individuals.
It has been proposed that asymptomatic carriers from the outside community could be introducing
virulent strains of Clostridium difficile into hospital settings and could potentially be the source of some of
the ribotypes that are typically healthcare-associated, such as PCR ribotype 027 (Clabots et al. 1992, Riggs
et al. 2007, Sheth 2013). However a PCR ribotyping study conducted among 1234 healthy individuals in
Japan challenges this hypothesis; it found that 94 of the participants (7.6%) carried C. difficile. The isolates
belonged to 37 different ribotypes, but none was 001/smz, the most frequently recovered ribotype from
CDAD patients in Japanese hospitals (Kato et al. 2001). These findings suggest that C. difficile is
widespread among asymptomatic individuals in the outside community, but ribotype 001/smz is not
particularly common in the community relative to healthcare settings. It has been posited that ribotype
8

001/smz might have specific virulence factors that favor successful transmission in healthcare settings
(Akerlund et al. 2006, Sawabe et al. 2007). A study of 149 healthy elderly individuals living in the United
Kingdom discovered that 4% carried C. difficile (Miyajima et al. 2011). In accordance with the data from
Japan, healthcare-associated ribotypes were under-represented. Ribotype 027 was not present among these
asymptomatic carriers. Only one individual was colonized with ribotype 106, a strain responsible for several
hospital outbreaks in the United Kingdom (Bauer et al. 2009, Freeman et al. 2010).
Conversely, several studies have noted much higher asymptomatic colonization rates among
hospitalized patients and residents of LTCFs, even though their risk of developing CDAD was not
significantly greater than that of other patients on the ward who were also treated with antibiotics (Clabots
et al. 1992, Shim et al. 1998, Riggs et al. 2007). In fact, one study of new admissions to a hospital found
that 21% were asymptomatically colonized with C. difficile and another study reported carriage rates of
51% in one LTCF (Clabots et al. 1992, Riggs et al. 2007). Clabots et al. (1992) noted that patients who had
previously been hospitalized in the medical center during the 30 days prior to admission were more likely
to be culture-positive for C. difficile than those who were not previously hospitalized at the institution (16%
vs. 7%, P<0.001), suggesting that many of these patients were colonized with C. difficile through past
healthcare exposures. Patients hospitalized in the past 30 days also comprised 57% of asymptomatic carriers
admitted to the ward (Clabots et al. 1992). Unfortunately the investigators did not include testing for nontoxigenic strains or strains that lacked either TcdA or TcdB in their methodology, so the actual C. difficile
carriage rate may be even greater than 51%. Of the toxigenic strains that were typed and carried by
asymptomatic patients, 37% were belonged to ribotype 027 (the NAP1 group referred to in their study).
This figure contrasts starkly with the reported carriage rates of epidemic ribotypes among healthy
asymptomatic carriers in both the Japan and the United Kingdom (Riggs et al. 2007). The presence of
virulent ribotypes that are frequently associated with C. difficile outbreaks such as 027 and 001 in hospitals
and LTCFs and their rarity in healthy individuals in the community who have few recent healthcare
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exposures suggests that a distinction between nosocomial ribotypes and community-associated ribotypes
exists.
Mortality and Morbidity of C. difficile in Nosocomial and Community Settings
One method for assessing the virulence of C. difficile is to examine mortality differences between
CDIs associated with nosocomial environments and those associated with the community. In the study
conducted by Norén et al. in Sweden, mortality rates were significantly higher for narrowly nosocomialassociated CDAD than for community-associated CDAD (15% vs 4% respectively; p=0.02) (Norén et al.
2004). Even when patients with severe comorbidity were omitted from the analysis, the mortality rate for
the narrowly nosocomial-associated CDAD (9%) was still significantly greater (p=0.04) than that of the
community-associated CDAD (1.7%) as seen in Table 1. Unfortunately the authors did not provide a
breakdown of mortality by ribotype, meaning that associations between mortality and individual ribotypes
that may be predominantly nosocomial or predominantly community-acquired could not be assessed.
However the aggregate differences in comorbidity-adjusted mortality between hospital-associated and
community-acquired ribotypes suggest that nosocomial ribotypes may in fact be more virulent and accord
with the prediction that nosocomial C. difficile infections will be more severe in healthcare settings where
attendant-borne transmission can occur.
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Another epidemiological study of C. difficile conducted in Monroe County, New York (Dumyati
et al. 2012) reported similar findings regarding the mortality of CA-CDI versus HA-CDI, as seen in Table
2. For the purposes of their study, the authors divided their participants into three groups based upon recent
healthcare exposures: (i) healthcare facility onset CDI (contains patients who had a positive fecal test for
C. difficile at least 48 hours after being admitted to a hospital or LTCF and corresponds with the healthcareassociated/narrowly nosocomial definition), (ii) community-onset healthcare-associated (CO-HCA) CDI
which was preceded by prior admission in the past 12 weeks to a hospital or LTCF, and (iii) communityassociated CDI. If a distinction exists between C. difficile ribotypes circulating in hospitals and those in the
community, patients with CO-HCA should share many of the same clinical characteristics with patients
diagnosed with HA-CDI and should have fewer characteristics in common with patients diagnosed with
CA-CDI. As seen in Table 2, mortality rates (which include only deaths directly attributable to CDI)
between the HA-CDI group (3.5%) and CO-HCA group (2.9%) were not significantly different (p=0.2).
However the CA-CDI group experienced no mortality, and when compared, the mortality rates in the CACDI group versus the nosocomial CDI group (HA-CDI plus CO HCA) were highly significant (p=0.0017).
On average, patients with CO-HCA required hospitalization more frequently (p=0.02) and were
hospitalized longer (p=0.03) than CA-CDI patients. The differences between these two groups accords with
the prediction that nosocomial CDI will be more severe than CA-CDI. Recurrence rates were the same in
the HA-CDI and CO-CDI group but were 10% lower for the CA-CDI group (p=0.17), but this was
statistically insignificant given the parameters of this study (definitional differences and subsequent
categorization of cases may play a role, as discussed later). Higher recurrence rates would be expected if
nosocomial ribotypes are more virulent, but it could also be attributable to host health given the recent
history of hospitalization or residence in a LTCF for the HA-CDI group. However, the mortality rates that
were adjusted for comorbidities still demonstrated a difference in deaths attributable to HA-CDI, CO-CDI,
and CA-CDI, which suggests that the C. difficile associated with CA-CDI are less virulent than those
associated with nosocomial CDI.
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The higher proportion of CA-CDI reported in this study (18%) relative to the aforementioned
proportion of 6% (McDonald et al. 2012) may reflect definitional differences because individuals who had
come into contact with other healthcare facilities as outpatients, visited family members in a hospital or
LTCF, or visited a doctor’s office were included in the CA-CDI group. In fact, 83% of CA-CDI patients
reported receiving healthcare at an outpatient office in the 12 weeks preceding the Monroe County study
and 21% reported visiting a healthcare facility without receiving treatment (Dumyati et al. 2012).
Ratios of symptomatic to asymptomatic infections for community populations relative to hospital
and LTCF populations can also indicate whether ribotypes circulating in a particular environment are more
virulent than those in another. The symptomatic:asymptomatic infections ratio for patients in a LTCF was
found to be 0.2 compared to a calculated ratio of 0.005 (P=0.001) given a 5% asymptomatic carriage rate
reported by Akerlund et al. (2011) for healthy individuals in the outside community (Norén et al. 2004,
Riggs et al. 2007). This difference suggests that nosocomial C. difficile ribotypes are indeed more virulent
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than community ribotypes, although estimates make it difficult to account for comorbidities that may make
patients in nosocomial settings more susceptible to symptomatic infections.
Durability and Virulence of C. difficile
Evolutionary theory proposes that durability and attendant-borne transmission may contribute
jointly to the evolutionary increases in pathogen virulence (see Introduction). A study of 4 hypervirulent
(for the purposes of their experiment, defined as strains that had caused epidemics with greater incidence,
severity, and mortality than non-hypervirulent strains) and 4 mild C. difficile strains found that the
hypervirulent strains (all variants of ribotype 027 collected from various locations in the U.S. and Canada)
sporulated earlier and produced more spores per total volume culture than mild strains (Merrigan et al.
2010). It was also noted that in general, the hypervirulent strains tended to sporulate with greater efficiency
and also produced a robust amount of toxins (Merrigan et al. 2010). Another study of toxin production and
spore-forming capabilities among several ribotypes, including the hospital and epidemic-associated
ribotype 027, found that 12 different isolates of 027 produced relatively large quantities of toxins and spores
(Vohra and Poxton 2011). In a follow-up study comparing ribotypes 001, 012, 027, 087, and 106, it was
observed that the epidemic 027 strain and two other prominent clinical strains—001 and 106—possessed
superior spore-forming capabilities compared to the other milder strains (Vohra et al. 2012). Furthermore,
it seems that environmental contamination of surfaces in healthcare settings with both spores and vegetative
C. difficile is high, especially when CDAD patients and asymptomatic carriers are present (Fekety et al.
1981, Riggs et al. 2007, Sethi et al. 2010). Spores have been demonstrated to survive for up to 5 months on
hospital surfaces (Kim et al. 1981). Such long persistence in the environment is likely to favor more virulent
ribotypes, and not surprisingly, the highly virulent ribotype 027 along with the typically nosocomial
ribotypes 001 and 106 all produced large numbers of spores. A general comparison of the spore-forming
capabilities of several clinically-relevant strains is presented in Table 3.
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RELEVANCE TO A UNIFIED UNDERSTANDING OF CLOSTRIDIUM DIFFICILE
VARIATION, BIOLOGY & PATHOLOGY
Attendant-borne Transmission & Durability
The increased mortality rates observed among nosocomial CDI and HA-CDAD patients relative to
CA-CDI and CA-CDAD patients in both the Örebro County, Sweden and Monroe County, New York
studies suggest that C. difficile ribotypes acquired from healthcare settings are indeed more virulent than
community-associated ribotypes. Comparisons of ribotypes carried by healthy asymptomatic carriers in the
outside community with few healthcare exposures with ribotypes carried by individuals exposed to
healthcare settings revealed that ribotypes often responsible for severe outbreaks of CDI, such as ribotype
027 and 001/smz, were not frequently isolated from healthy individuals, but were very common in LTCFs
and hospitals (Stubbs et al. 1999, Kato et al. 2001, Riggs et al. 2007, Sawabe et al. 2007, Miyajima et al.
2011). This suggests that nosocomial ribotypes may be distinct from community-associated ribotypes and
likely possess virulence characteristics that make them well-adapted for transmission in healthcare settings
(Akerlund et al. 2011). The presence of these typically nosocomial ribotypes in the outside community may
reflect cycling, and such ribotypes would be expected to cause more severe cases that would garner medical
attention and thus result in the ribotype cycling back to healthcare settings. Durability of C. difficile spores
in hospital settings should also favor increased virulence, and accordingly ribotypes associated with
outbreaks and severe disease were some of the most efficient and prolific at sporulation (Akerlund et al.
2008, Merrigan et al. 2010, Vohra and Poxton 2011, Vohra et al. 2012).
This study has demonstrated that attendant-borne transmission as well as the persistence and
durability of certain C. difficile ribotypes in healthcare environments are associated with the observed
increase in virulence of nosocomial ribotypes relative to community ribotypes over the past thirty years.
The independent emergence of several clinically-relevant strains (027, 001, 106, and 078) associated with
increased severity of disease and responsible for multiple C. difficile outbreaks in such a short evolutionary
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timeframe (He et al. 2010) also suggests that selective pressures, such as those provided by attendant-borne
transmission, have played an important role in the observed increase of C. difficile morbidity and mortality.
In order to gain a more comprehensive understanding of the disease ecology and evolution of
Clostridium difficile virulence, there remain many aspects of the organism’s life cycle and pathogenicity
that must be evaluated. More detailed prospective studies that include asymptomatic carriers and combine
epidemiological approaches with isolate typing would be helpful for further evaluating the role of attendantborne transmission and how asymptomatic carriers may contribute to the cycling of nosocomial ribotypes
in the outside community. Understanding the role of various C. difficile virulence factors, host immunity
factors, and antibiotics of in the transmission and pathogenicity of C. difficile through an evolutionary
context could also contribute to efforts aimed at preventing the emergence of highly virulent strains.
Virulence Factors
Clostridium difficile’s primary mechanism of virulence has been thought to be the production of an
enterotoxin and cytotoxin, known respectively as TcdA and TcdB, but now the picture seems much less
clear (Deneve et al. 2009). Initially it was believed that TcdA, which has been linked to fluid accumulation
and inflammation, was responsible for the majority of C. difficile-related disease. TcdA has also been
demonstrated to increase the permeability of colonic epithelial layers through disruption of tight junctions
in cases of pseudomembranous colitis (Voth and Ballard 2005). However recent studies have shown that
TcdA- C. difficile such as ribotype 017 are capable of causing CDAD, and it appears that both TcdA and
TcdB can trigger cell apoptosis albeit through different pathways (Voth and Ballard 2005). TcdB is now
believed to be the more potent toxin of the two due to its higher rate of enzymatic activity and ability to
cause a great deal of damage to the intestinal epithelium in a relatively short amount of time (Voth and
Ballard 2005). The majority of the clinically-relevant strains discussed in this paper and listed in Table 3
are known to produce both TcdA and TcdB, but there are many other factors associated with toxin
production that could contribute to virulence, including duration of toxin production, quantity of toxins
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produced, and perhaps even host factors. Several important intrinsic virulence factors of C. difficile are
listed below in Table 4.

Epidemic ribotype 027’s toxin production regulatory mechanisms have been studied with the hope
of discovering why this particular ribotype is capable of causing such severe disease. Several mutations in
the tcdC gene, which codes for the TcdC regulatory protein, are thought to contribute to the production of
a faulty TcdC protein, allowing 027 to continue producing toxins at high levels during its life cycle long
after most ribotypes have reduced toxin output (Curry et al. 2006, Dupuy et al. 2008, Saxton et al. 2009,
Merrigan et al. 2010). Ribotype 027 also possesses the ability to produce an additional toxin known as
17

binary toxin CDT, which is able to induce actin rearrangement in enterocytes, creating cell membrane
protrusions that envelope C. difficile. This process is believed to aid 027 in adhering to the intestinal
epithelium, which is required in order for C. difficile to cause disease (Schwan et al. 2009). CDT+ strains
have been linked with greater disease severity, and not surprisingly, the ability to produce CDT has been
on the rise in ribotype 027 isolates, with the incidence of CDT+ isolates climbing upwards of 40% in the
United Kingdom (Stabler et al. 2009). Some ribotype 078 isolates have been reported to produce CDT as
well and to exhibit highly virulent characteristics similar to epidemic ribotype 027 (Goorhuis et al. 2008).
Interestingly, the presence or absence of certain amino acids has been found to affect C. difficile
toxin yields in vitro which raises the question of the role of competition between gut bacteria for resources
in virulence regulation. A study of gnotic mice colonized with VPI 10463/ribotype 087 (a strain known for
high toxin production but isn’t typically nosocomial) reported that a change of diet reduced fecal TcdA
yields by up to 100-fold without affecting bacterial numbers, and the mortality due to C. difficile decreased
significantly (Mahe et al. 1987). Additionally, an in vivo reduction in pathology was also observed when
colonizing strains of E. coli and Bifidobacterium bifidum were introduced, leading to decreased cytotoxin
yields from the VPI 10463/ribotype 087 strain (Corthier and Muller 1988). VPI 10463/ribotype 087 is
known to have high toxin yields but is not known to sporulate well, leading some to suggest that the decrease
in toxin production could signify a shift in survival strategies in response to competition (Akerlund et al.
2006). Similar studies conducted with highly virulent, spore-producing ribotypes could be useful for
clarifying the role of interspecific competition for resources on the virulence of different C. difficile strains.
Adherence factors such as adhesin proteins, flagella, and fimbriae have historically received less
attention than the various toxins of C. difficile, but they may play a significant role in both colonization and
virulence. One adhesin protein known as Cwp66 has been demonstrated to help C. difficile adhere to
enterocytes and is a target of antibodies (Waligora et al. 2001). In addition to granting motility, C. difficile
flagella also enable the bacteria to better adhere to enterocytes and possibly subvert host defenses, leading
to increased colonization success (Tasteyre et al. 2001, Stabler et al. 2009). Fimbriae have also been
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implicated as possible mechanism through which C. difficile could increase its adhesion abilities, but so far
there have been few studies, with most being inconclusive (Borriello et al. 1988). Further studies on
adhesion mechanisms, particularly those of highly virulent ribotypes, could identify potential targets for
new antimicrobials that could then be used to prevent the adhesion of C. difficile to the intestinal epithelium.
Role of Antibiotic Therapy
As previously mentioned, antibiotic exposure is thought to play a crucial role in the majority of C.
difficile cases by causing dysbiosis and compromising the colonization barrier (Deneve et al. 2008). Until
recently, little attention has been paid to other potential effects of antibiotics on the regulation of C. difficile
virulence factors. New evidence suggests that certain antibiotics may act as a stimulus or inducer signaling
for the increase in production of virulence factors and spores. One study demonstrated that fluoroquinolones
can induce increased spore germination and toxin production in ribotypes 027 and 001 in a human gut
model (Saxton et al. 2009). Toxin production was also shown to be increased and to begin earlier in four
C. difficile strains exposed to sub-inhibitory levels of metronidazole, vancomycin, linezolid (Gerber et al.
2008). Toxin production and sporulation are not the only virulence-related functions affected by antibiotics;
genes encoding for three different adherence factors are also reportedly upregulated in the presence of
sublethal levels of clindamycin and ampicillin as well (Deneve et al. 2008). The implications of these
findings could prove to be extremely important to reducing antimicrobial-associated CDI, for creating
policies guiding antibiotic use during C. difficile outbreaks, and for the production of new antimicrobials
that C. difficile is both susceptible to and unlikely to produce excess virulence factors in response to
treatment with them.
Host Factors
Variations in host immunity are a relatively new consideration in the investigation of CDI risk
factors, but they could prove to be important for understanding infection in asymptomatic carriers. A
prospective study of 810 patients admitted to the Minneapolis Veterans Affairs Medical Center and the

19

New England Deaconess Hospital found that the 192 identified asymptomatic carriers were less likely to
develop CDAD during their stay compared with non-carriers (1.0% vs. 3.6%). Even with the addition of
CDAD risk factors like treatment with antibiotics, asymptomatic carriers still had a lower CDAD rate (1.1%
vs. 4.5%) compared to non-colonized individuals (Shim et al. 1998). Whether this represents some sort of
host-immune interaction and subsequently conferred immunity to C. difficile-related illness is unclear, but
it does suggest that most hospital patients diagnosed with CDAD are not falling ill from their own native
C. difficile flora after receiving antibiotic therapy. The difference between the rates of CDAD in noncolonized individuals versus non-colonized individuals who received antibiotic therapy (3.6% vs. 4.5%)
was minimal, suggesting that treatment with antibiotics might not be the most significant risk factor for
CDAD in a hospital setting despite antibiotics being thought to disrupt the native intestinal microbiota
(Deneve et al. 2008). Alternatively, colonization status prior to admission and in particular, colonization
with particularly pathogenic nosocomial strains after admission could play a significant role in the
development of CDAD. Further studies are needed to evaluate this possibility and to fully explain the role
of host immune factors in determining what distinguishes individuals who become symptomatic when
colonized with C. difficile from those who remain healthy as carriers.
Implications for Public Health
Examining the spread of C. difficile in hospitals and other healthcare settings within an evolutionary
context could provide new insights and useful tools for stopping its spread and manipulating the virulence
of some of the more deadly nosocomial strains into milder ones. Attendant-borne transmission is easily
preventable when the proper protocol is established and followed consistently in healthcare settings. One
study that evaluated the efficacy of regular glove use when encountering CDI patients demonstrated
significantly reduced CDI incidence and asymptomatic infections in comparison to control wards (Johnson
et al. 1990). Since alcohol-based hand sanitizers are ineffective at killing C. difficile spores, it is also
important that hand washing with soap and water and/or a chlorine agent is performed after coming into
contact with a CDI patient or wards where CDI patients reside (Gerding et al. 2008). This is equally as
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important in hospitals as it is in long-term care facilities, where skin and environmental contamination are
common (Riggs et al. 2007). Implementing the use of gloves by all healthcare personnel when attending to
C. difficile infected patients, reminding staff to use hot water and soap to wash their hands after working
with CDAD patients, and educating hospital visitors and all personnel on the need for glove use and/or
washing hands with soap or chlorine agents is essential to any successful infection control campaign that
seeks to prevent attendant-borne transmission.
Eliminating spores and preventing C. difficile’s ability to persist on hospital surfaces is also crucial
to any plan for reducing the virulence and incidence of CDIs. A 2007 study conducted among long-term
care facility residents found that even asymptomatic carriers of C. difficile had a high rate of skin (61%)
and environmental contamination (59%). 87% of isolates from skin swabs and 58% of isolates from
environmental surfaces matched strain types found concurrently in resident fecal samples. Additionally,
spores from the residents’ skin were found to be easily transferred to the investigators’ hands, which could
increase attendant-borne transmission and further contribute to the emergence of highly virulent variants
(Riggs et al. 2007). C. difficile spores are capable of persisting on hospital environmental surfaces for up to
5 months (Kim et al. 1981), and epidemic strains have been shown to actually increase sporulation in
response to exposure to ineffective disinfectants (i.e. non-chlorine-based cleaning agents), meaning that
infection control measures such as thoroughly cleaning frequently contacted surfaces and rooms of CDAD
patients may be counterproductive to controlling or preventing C. difficile outbreaks if the proper
sanitization procedures are not being used (Wilcox and Fawley 2000). Rooms of CDAD patients must be
thoroughly cleaned using 10% sodium hypochlorite for all spores to be eliminated (Gerding et al. 2008).
Ultimately such steps should negate the fitness advantages associated with host exploitation by durable,
attendant-borne C. difficile. Consequently, mild strains should be evolutionarily favored.
Reducing attendant-borne transmission of Clostridium difficile should also help to reduce the
incidence of antibiotic-resistant strains seen in hospitals. When governed by proper stewardship protocols,
antibiotics are typically only administered when disease is severe, which is often associated with highly
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virulent organisms. Logic would suggest that virulent strains of C. difficile that greatly exploit their hosts
and therein by cause severe symptoms tend to be the strains most frequently treated with antibiotics and the
strains most likely to cause a patient to seek treatment in a hospital setting. Accordingly, attendant-borne
transmission should favor these highly virulent, highly exploitative strains that tend to most often require
antibiotics. If attendant-borne transmission is reduced, incidence of these severe infections is reduced, and
the need for treating these severe infections with antibiotics is also reduced. Administering fewer antibiotics
to treat these infections should lessen the probability that a particular strain will be exposed to and
subsequently develop resistance to a given antibiotic.
Finally, improving surveillance for CDI and particularly for asymptomatic CDI in healthcare
settings could help prevent further outbreaks and alert healthcare institutions to the presence of C. difficile
potentially before symptomatic cases begin to appear. Typing of strains needs to be established as a regular
diagnostic protocol along with antibiotic susceptibility testing, so as to minimize resistance and to raise the
attention of hospital staff if individuals harboring particularly virulent C. difficile variants, especially those
known for robust spore production, are admitted. One of the reasons proposed for the sharp decline observed
in ribotype 027 CDIs since late 2007 in the United Kingdom has been the implementation of mandatory
reporting along with making typing of C. difficile isolates widely available to healthcare providers through
the Clostridium difficile Ribotyping Network (established in 2007) and strictly limiting the use of antibiotics
associated with CDI (Cairns et al. 2012, Wilcox et al. 2012). Lack of continuity and consistency between
the use of typing techniques, definitions with respect to community-associated CDI, and definitions for
what constitutes a healthcare exposure are issues that limit the accessibility of studies and hinder scientific
collaboration across regions (Freeman et al. 2010). Establishing and implementing global standards for
optimal isolate typing techniques, definitions for CDI, definitions for healthcare exposures would facilitate
international efforts for C. difficile epidemiological tracking and contribute to the creation of a unified
understanding of Clostridium difficile variation, biology, and pathology.
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